• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

黏液样脂肪肉瘤中的一种新型FUS/CHOP嵌合体。

A novel FUS/CHOP chimera in myxoid liposarcoma.

作者信息

Panagopoulos I, Mertens F, Isaksson M, Mandahl N

机构信息

Department of Clinical Genetics, Lund University Hospital, Lund, S-221 85, Sweden.

出版信息

Biochem Biophys Res Commun. 2000 Dec 29;279(3):838-45. doi: 10.1006/bbrc.2000.4026.

DOI:10.1006/bbrc.2000.4026
PMID:11162437
Abstract

The cytogenetic hallmark of myxoid liposarcoma is the chromosomal aberration t(12;16)(q13;p11), which is pathognomonic for this tumor type. The translocation results in the hybrid gene FUS/CHOP, where the central and C-terminal parts of FUS, coding for the RNA binding domain and the RGG triplet motif, are replaced by the full length CHOP protein. Thus, CHOP is under the control of the FUS promoter and the FUS/CHOP chimera contains the 5'-terminal part of FUS which provides a transcriptional activation function. Although different structural variations of the FUS/CHOP chimeric transcript have been reported, none of them contains the parts of FUS encoding the RNA binding properties. An explanation is the location of the genomic breakpoint in FUS, which frequently occurs in the region spanning exon 5 to intron 8. We describe here a case of myxoid liposarcoma containing two novel FUS/CHOP chimeric transcripts and with the breakpoint occurring in intron 14 of FUS. Reverse transcription-polymerase chain reaction, using FUS forward and CHOP reverse primers, amplified strongly a 2.1-kbp DNA fragment and weakly a 0.9-kbp DNA fragment. Direct sequencing showed that in the 2.1-kbp transcript nt 1474, which corresponds to the third nucleotide of exon 14 of FUS, was in-frame fused to exon 2 of CHOP. In the 0.9-kbp DNA fragment, exon 3 of FUS was in-frame fused to exon 2 of CHOP. Genomic analyses revealed that the breaks were located at the end of exon 14/beginning of intron 14 of FUS and in intron 1 of CHOP and that microdeletions had occurred in the close vicinity of the breakpoints.

摘要

黏液样脂肪肉瘤的细胞遗传学特征是染色体畸变t(12;16)(q13;p11),这是该肿瘤类型的特征性表现。这种易位导致融合基因FUS/CHOP的形成,其中FUS编码RNA结合结构域和RGG三联体基序的中央和C末端部分被全长CHOP蛋白取代。因此,CHOP受FUS启动子的控制,FUS/CHOP嵌合体包含FUS的5'-末端部分,该部分提供转录激活功能。尽管已经报道了FUS/CHOP嵌合转录本的不同结构变异,但它们均不包含编码RNA结合特性的FUS部分。一种解释是FUS中基因组断点的位置经常出现在跨越外显子5至内含子8的区域。我们在此描述了一例黏液样脂肪肉瘤,其包含两种新型FUS/CHOP嵌合转录本,断点发生在FUS的内含子14中。使用FUS正向引物和CHOP反向引物进行逆转录-聚合酶链反应,强烈扩增出一个2.1-kbp的DNA片段,微弱扩增出一个0.9-kbp的DNA片段。直接测序显示,在2.1-kbp转录本中,对应于FUS外显子14第三个核苷酸的nt 1474与CHOP的外显子2框内融合。在0.9-kbp DNA片段中,FUS的外显子3与CHOP的外显子2框内融合。基因组分析显示,断点位于FUS外显子14的末端/内含子14的起始处以及CHOP内含子1中,并且在断点附近发生了微缺失。

相似文献

1
A novel FUS/CHOP chimera in myxoid liposarcoma.黏液样脂肪肉瘤中的一种新型FUS/CHOP嵌合体。
Biochem Biophys Res Commun. 2000 Dec 29;279(3):838-45. doi: 10.1006/bbrc.2000.4026.
2
Characteristic sequence motifs at the breakpoints of the hybrid genes FUS/CHOP, EWS/CHOP and FUS/ERG in myxoid liposarcoma and acute myeloid leukemia.黏液样脂肪肉瘤和急性髓性白血病中融合基因FUS/CHOP、EWS/CHOP和FUS/ERG断点处的特征性序列基序。
Oncogene. 1997 Sep;15(11):1357-62. doi: 10.1038/sj.onc.1201281.
3
Chimeric TLS/FUS-CHOP gene expression and the heterogeneity of its junction in human myxoid and round cell liposarcoma.嵌合型 TLS/FUS-CHOP 基因表达及其在人黏液样和圆形细胞脂肪肉瘤中连接区的异质性
Am J Pathol. 1995 Nov;147(5):1221-7.
4
FUS/TLS-CHOP chimeric transcripts in liposarcoma tissues.脂肪肉瘤组织中的FUS/TLS-CHOP嵌合转录本
Jpn J Clin Oncol. 1995 Dec;25(6):234-9.
5
A novel type of EWS-CHOP fusion gene in myxoid liposarcoma.黏液样脂肪肉瘤中的一种新型EWS-CHOP融合基因。
Biochem Biophys Res Commun. 2006 Sep 22;348(2):437-40. doi: 10.1016/j.bbrc.2006.07.085. Epub 2006 Jul 28.
6
Fusion of the EWS and CHOP genes in myxoid liposarcoma.黏液样脂肪肉瘤中EWS和CHOP基因的融合
Oncogene. 1996 Feb 1;12(3):489-94.
7
Two distinct FUS breakpoint clusters in myxoid liposarcoma and acute myeloid leukemia with the translocations t(12;16) and t(16;21).黏液样脂肪肉瘤和急性髓系白血病中分别存在两个不同的FUS断点簇,伴有t(12;16)和t(16;21)易位。
Oncogene. 1995 Sep 21;11(6):1133-7.
8
Characteristics of genomic breakpoints in TLS-CHOP translocations in liposarcomas suggest the involvement of Translin and topoisomerase II in the process of translocation.脂肪肉瘤中TLS-CHOP易位的基因组断点特征表明,转位蛋白和拓扑异构酶II参与了易位过程。
Oncogene. 1999 Jan 21;18(3):721-9. doi: 10.1038/sj.onc.1202364.
9
Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases.P53状态、TLS-CHOP融合转录本结构及组织学分级对黏液样脂肪肉瘤的预后影响:82例分子及临床病理研究
Clin Cancer Res. 2001 Dec;7(12):3977-87.
10
Monoclonality of multifocal myxoid liposarcoma: confirmation by analysis of TLS-CHOP or EWS-CHOP rearrangements.多灶性黏液样脂肪肉瘤的单克隆性:通过分析 TLS-CHOP 或 EWS-CHOP 重排进行确认。
Clin Cancer Res. 2000 Jul;6(7):2788-93.

引用本文的文献

1
-The Most Common Rearranged Gene in Soft Tissue Lesions, Which Also Occurs in Different Bone Lesions: An Updated Review.软组织病变中最常见的重排基因,其也见于不同的骨病变:最新综述
Diagnostics (Basel). 2021 Jun 15;11(6):1093. doi: 10.3390/diagnostics11061093.
2
Rationale for Early Detection of Translocation-Associated Sarcoma Biomarkers in Liquid Biopsy.液体活检中易位相关肉瘤生物标志物早期检测的原理
Cancers (Basel). 2021 Feb 16;13(4):824. doi: 10.3390/cancers13040824.
3
Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma.
阿昔替尼在黏液样脂肪肉瘤中具有抗血管生成和抗肿瘤活性。
Sarcoma. 2016;2016:3484673. doi: 10.1155/2016/3484673. Epub 2016 Oct 16.
4
Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network.曲贝替定治疗晚期滑膜肉瘤:一项来自四个欧洲机构和意大利罕见癌症网络的多中心回顾性研究。
Anticancer Drugs. 2015 Jul;26(6):678-81. doi: 10.1097/CAD.0000000000000228.
5
Myxoid liposarcoma with cartilaginous differentiation: a case study with cytogenetical analysis.伴有软骨分化的黏液样脂肪肉瘤:一项细胞遗传学分析的病例研究
Korean J Pathol. 2013 Jun;47(3):284-8. doi: 10.4132/KoreanJPathol.2013.47.3.284. Epub 2013 Jun 25.
6
A case of myxoid liposarcoma of the breast.一例乳腺黏液样脂肪肉瘤
Int J Clin Exp Pathol. 2013 Jun 15;6(7):1432-6. Print 2013.
7
Variation in myxoid liposarcoma: Clinicopathological examination of four cases with detectable TLS-CHOP or EWS-CHOP fusion transcripts whose histopathological diagnosis was other than myxoid liposarcoma.黏液样脂肪肉瘤的变异:4例组织病理学诊断并非黏液样脂肪肉瘤但可检测到TLS-CHOP或EWS-CHOP融合转录本病例的临床病理检查
Oncol Lett. 2012 Feb;3(2):293-296. doi: 10.3892/ol.2011.480. Epub 2011 Nov 15.
8
Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option.黏液样脂肪肉瘤的激酶组分析揭示了 NF-κB 通路激酶活性和酪蛋白激酶 II 抑制作用,这可能是一种潜在的治疗选择。
Mol Cancer. 2010 Sep 23;9:257. doi: 10.1186/1476-4598-9-257.
9
Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience.分子生物学分析在脂肪肉瘤诊断和临床管理中的附加价值:30 年单机构经验。
Ann Surg Oncol. 2010 Mar;17(3):686-93. doi: 10.1245/s10434-009-0806-9.
10
Multifocal myxoid liposarcoma--metastasis or second primary tumor?: a molecular biological analysis.多灶性黏液样脂肪肉瘤——转移瘤还是第二原发肿瘤?:分子生物学分析。
J Mol Diagn. 2010 Mar;12(2):238-43. doi: 10.2353/jmoldx.2010.090117. Epub 2010 Jan 21.